Tianye Zhao

Mr. Tianye Zhao

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
WQWen Qi
Wen Qi
LZLiting Zhou
Liting Zhou
TZTianye Zhao
Tianye Zhao
SDShuang Ding
Shuang Ding
QXQi Xu
Qi Xu
LYLin Ye
Lin Ye

1 January 2021 in Journal of Scholarly Publishing
Verified
Journal Article
Closed access
TZTianye Zhao
Tianye Zhao
TDTiancong Dai
Tiancong Dai
ZLZhijun Lun
Zhijun Lun
YGYanli Gao
Yanli Gao
The aim of this study was to analyze the features of retracted articles by authors affiliated with hospitals in mainland China. We searched the PubMed, Web of Science, and Retraction Watch databases for retractions and identified the following characteristics of each retracted article: publisher, open access status, impact factor of the journal that retracted the article, any PubPeer comments recorded before the retraction, status of the hospital where the authors worked, and any response to the retraction from the authors. We found 521 retractions, primarily by authors at grade A, third-level hospitals located in a limited number of regions of mainland China, and found that the journals that had published and later retracted the articles tended to have a medium to high impact factor. The main reasons for retraction were data manipulation, fabrication, or fraud; errors made by the authors; or plagiarism. Few of the retracted publications had PubPeer comments before their retraction. This is the first report to focus on retracted research coming out of hospitals in mainland China. The large number of retractions for Chinese hospitals is worrying. The results suggest that some retractions were related to third parties that provided editorial and other services.

16 February 2021 in PeerJ
Verified
Journal Article
Open access
PDF file
LQLili Qin
Lili Qin
YWYueqi Wang
Yueqi Wang
NYNa Yang
Na Yang
YZYangyu Zhang
Yangyu Zhang
TZTianye Zhao
Tianye Zhao
JJJiang Jing
Jiang Jing
Background Tissue inhibitor of metalloproteinase 1 (TIMP-1) has recently been shown to be dependent on or independent of Matrix metalloproteinases (MMPs) in its roles in tumorigenesis and progression. This appreciation has prompted various studies assessing the prognostic value of TIMP-1 in patients with gastrointestinal cancer, however, the conclusions were still inconsistent. The aim of this study was to assess the prognostic value of TIMP-1-immunohistochemistry (IHC) staining and pretreatment serum/plasma TIMP-1 level in gastrointestinal cancer survival as well as the association between TIMP-1 and clinicopathologic features. Methods The meta-analysis was registered in the International Prospective Register of Systematic Reviews (PROSPERO; Registration NO. CRD42020185407) and followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. A highly sensitive literature search was performed in electronic databases including PubMed, EMBASE and the Cochrane Library. Heterogeneity analysis was conducted using both chi-square-based Q statistics and the I2 test. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to assess the prognostic value of TIMP-1 using the fixed-effects model. Odds ratios (ORs) with 95% CIs were calculated to evaluate the associations between TIMP-1 and clinicopathological characteristics. The meta-analysis was conducted using STATA 12.0 software. Results A total of 3,958 patients from twenty-two studies were included in the meta-analysis. Elevated TIMP-1 levels were significantly associated with poor survival in gastrointestinal cancer (TIMP-1-IHC staining: HR = 2.04, 95% CI [1.59–2.61], I2 = 35.7%, PQ = 0.156; pretreatment serum/plasma TIMP-1 levels: HR = 2.02, 95% CI [1.80–2.28], I2 = 0%, PQ = 0.630). Moreover, clinicopathological parameter data analysis showed that elevated TIMP-1 levels were significantly associated with lymph node metastasis (N1/N2/N3 vs N0: OR = 2.92, 95% CI [1.95–4.38]) and higher TNM stages (III/IV vs I/II: OR = 2.73, 95% CI [1.23–6.04]). Conclusion Both TIMP-1-positive IHC staining and high serum/plasma TIMP-1 levels are poor prognostic factors for the survival of gastrointestinal cancer. In addition, TIMP-1 overexpression was correlated with more advanced clinicopathological features.

18 September 2023 in Journal of Viral Hepatitis
Verified
Journal Article
Open access
HHHua He
Hua He
YWYanhua Wu
Yanhua Wu
ZJZhifang Jia
Zhifang Jia
HXHongqin Xu
Hongqin Xu
YPYuchen Pan
Yuchen Pan
JJJiang Jing
Jiang Jing
The aim of this study was to determine whether the age-Male-ALBI-Platelet (aMAP) score is applicable in community settings and how to maximise its role in risk stratification. A total of thousand five hundred and three participants had an aMAP score calculated at baseline and were followed up for about 10 years to obtain information on liver cancer incidence and death. After assessing the ability of aMAP to predict liver cancer incidence and death in terms of differentiation and calibration, the optimal risk stratification threshold of the aMAP score was explored, based on absolute and relative risks. The aMAP score achieved higher area under curves (AUCs) (almost all above 0.8) within 10 years and exhibited a better calibration within 5 years. Regarding absolute risk, the risk of incidence of and death from liver cancer showed a rapid increase after an aMAP score of 55. The cumulative incidence (5- year: 8.3% vs. 1.3% and 10- year: 20.9% vs. 3.6%) and mortality (5- year: 6.7% vs. 1.1% and 10-year: 17.5% vs. 3.1%) of liver cancer in individuals with an aMAP score of =55 were significantly higher than in those with a score of <55 (Grey's test p < .001). In terms of relative risk, the risk of death from liver cancer surpassed that from other causes after an aMAP score of =55 [HR= 1.38(1.02- 1.87)]. Notably, the two types of death risk had opposite trends between the subpopulation with an aMAP score of =55 and < 55. To conclude, this study showed the value of the aMAP score in community settings and recommends using 55 as a new risk stratification threshold to guide subsequent liver cancer screening.